Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Provides free water and sodium chloride to expand extracellular fluid volume and correct electrolyte imbalances. Dextrose is metabolized to carbon dioxide and water, providing calories and preventing ketosis. Sodium chloride dissociates into sodium and chloride ions, maintaining osmotic pressure and acid-base balance.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
FDA-approved for fluid and electrolyte replacement,Treatment of dehydration,Maintenance of fluid and electrolyte balance,Used as a vehicle for intravenous drug administration (off-label),Correction of hyponatremia (off-label)
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion; dose determined by fluid and electrolyte requirements. Typical adult: 500-1000 m L at 50-100 m L/hour, adjusted based on clinical status.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Dextrose: not applicable (endogenous substrate); glucose half-life ~1.5–2 hours in circulation under normal conditions, prolonged in hyperglycemia. Sodium chloride: not applicable as ions are electrolytes with no elimination half-life; renal clearance depends on glomerular filtration and tubular reabsorption.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose undergoes glycolysis and subsequent metabolism via the tricarboxylic acid cycle. Sodium and chloride are primarily excreted unchanged by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Dextrose is fully metabolized to carbon dioxide and water; no significant renal excretion of intact dextrose. Sodium chloride is excreted renally; sodium and chloride ions are eliminated via kidneys, with excretion proportional to intake and renal function. No biliary or fecal elimination of intact components.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Dextrose: not bound to plasma proteins. Sodium chloride: sodium and chloride ions are not protein-bound (<1% bound).
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Dextrose: ~0.2 L/kg (distributes in extracellular fluid). Sodium: ~0.2–0.3 L/kg (mainly extracellular). Chloride: ~0.2–0.3 L/kg. Clinical meaning: Vd approximates extracellular fluid volume; expansion of Vd indicates fluid overload.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% for both dextrose and sodium chloride. Not administered by other routes.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
No specific renal dose adjustment; use caution in renal impairment due to sodium load. Monitor fluid status. GFR <30 m L/min: consider reduced rate or use of alternative fluids.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific hepatic adjustment required. Use standard dosing; monitor for fluid overload in severe hepatic impairment (Child-Pugh C).
No dosage adjustment required for hepatic impairment.
Weight-based: 5-10 m L/kg/dose as maintenance fluid, administered at 100-150 m L/kg/day for infants and 60-80 m L/kg/day for older children, adjusted per clinical need.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Start at lower end of infusion rate (50 m L/hour) and titrate based on renal function and cardiac status. Monitor for hyperglycemia and fluid overload due to reduced renal function and comorbidities.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of fluid overload, especially in patients with heart failure, renal impairment, or edema,Hyperglycemia in diabetic patients or those with glucose intolerance,Hypersensitivity reactions (rare),Electrolyte disturbances (e.g., hypernatremia, hyponatremia, hyperchloremia) with improper use,Not for use in patients with increased intracranial pressure or severe renal impairment without careful monitoring
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperglycemia with severe dehydration,Intracranial or intraspinal hemorrhage (when used as a vehicle),Severe electrolyte disturbances without correction,Allergy to dextrose or sodium chloride
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No specific food interactions, but patients should avoid high-sodium foods to prevent hypernatremia.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Dextrose 5% and sodium chloride 0.9% are not teratogenic. No known fetal risks at recommended doses. First trimester: No evidence of harm. Second trimester: No risk. Third trimester: No risk.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Compatible with breastfeeding. Dextrose and sodium chloride are normal constituents of breast milk. M/P ratio not applicable as they are endogenous substances. No adverse effects expected.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No dose adjustment required. Pregnancy does not significantly alter the pharmacokinetics of dextrose or sodium chloride. Dosing is based on clinical need for fluid and electrolyte replacement.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This solution is isotonic (308 m Osm/L) and provides 170 kcal/L from dextrose. It is contraindicated in patients with hyperglycemia, hypernatremia, or fluid overload. Use with caution in renal impairment, heart failure, or elderly patients. Monitor serum glucose, sodium, and volume status. Do not administer if solution is discolored or contains particulates.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Inform your healthcare provider if you have diabetes, high blood pressure, or heart failure.,Tell your doctor if you experience headache, swelling, shortness of breath, or dry mouth.,This medication provides sugar and salt; avoid additional sodium in your diet unless directed.,Report any pain, redness, or swelling at the IV site.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Provides free water and sodium chloride to expand extracellular fluid volume and correct electrolyte imbalances. Dextrose is metabolized to carbon dioxide and water, providing calories and preventing ketosis. Sodium chloride dissociates into sodium and chloride ions, maintaining osmotic pressure and acid-base balance.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by fluid and electrolyte requirements. Typical adult: 500-1000 m L at 50-100 m L/hour, adjusted based on clinical status.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose 5% and sodium chloride 0.9% are not teratogenic. No known fetal risks at recommended doses. First trimester: No evidence of harm. Second trimester: No risk. Third trimeste. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.